Mechanism
Oral small-molecule CNS drug; proprietary multi-target pharmacology
Assets acting on this target.
- Class
- Oral small-molecule CNS drug; proprietary multi-target pharmacology from IRLAB's Integrative Screening Process platform (specific receptor(s) not publicly disclosed)
- Pathway
- Hypothesized to reverse disruption in cortical-to-subcortical nerve signaling, a proposed mechanism underlying apathy in Parkinson's disease and other neurological disorders
- Notes
- original target text: Oral small-molecule CNS drug; proprietary multi-target pharmacology from IRLAB's Integrative Screening Process platform (specific receptor(s) not publicly disclosed)
Research
Sign in to access ResearchExplore this mechanism at different depths
Research adds deeper and simplified explanation variants while preserving the same scientific register and source caveats.
0 of 0 assets
No assets match these filters.